Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jung Won Shin

Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector. 
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.

Set Alert for Articles By Jung Won Shin

Latest From Jung Won Shin

Korea To Reform Reimbursement Management To Cut Expenditure

To trim the healthcare financial burden and boost the country’s national health insurance coverage as planned, South Korea will introduce a drug re-evaluation system to adjust prices of both novel and generic drugs, drawing a negative response from the pharma industry.

South Korea Reimbursement

Invossa Gene Therapy Controversy Grows As Government, Patients Take Action

While the eventual fate of Kolon Life’s gene therapy Invossa is still undecided after interim results from an ongoing probe into its composition, controversy over the product is growing as patients seek compensation from the company and government, and calls grow for a wider investigation.

South Korea Gene Therapy

South Korea's ADEL Innovates With Anti-Tau Antibody For Alzheimer’s Disease

Emerging Company Profile: ADEL Inc. CEO Seung-Yong Yoon tells Scrip how its anti-tau antibody brings something different to the table in the challenging field of Alzheimer's disease and what's in store for the South Korean bioventure.

South Korea Neurology

What Can Korea Learn From The Invossa Trial And Error Case?

South Korea, which has recently delayed the political passage of a cutting-edge regenerative medicine and biologics act, should learn from the latest unprecedented incident involving Kolon Life Science’s cell and gene therapy Invossa, and pre-emptively make preparations and guidelines to better deal with such pioneering medicines, an industry expert tells Scrip.

South Korea Gene Therapy

Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.

Deals Commercial

Korea Overhauls Rules On Generics To Enhance Responsibility And Competitiveness

Following the worldwide generic valsartan quality woes, South Korea moves to improve the quality of generics and will eventually scrap joint bioequivalence tests, while implementing effective price cuts to later products to curb excessive competition and improve pharma firms’ responsibility for their drugs.

Regulation South Korea
See All